Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP219216.RA7IrBPkSkRE1Lkw2Baysoat_RS-BpTeLWAPEWe4ACkrI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP219216.RA7IrBPkSkRE1Lkw2Baysoat_RS-BpTeLWAPEWe4ACkrI130_assertion type Assertion NP219216.RA7IrBPkSkRE1Lkw2Baysoat_RS-BpTeLWAPEWe4ACkrI130_head.
- NP219216.RA7IrBPkSkRE1Lkw2Baysoat_RS-BpTeLWAPEWe4ACkrI130_assertion description "[To clarify this apparent discrepancy, 48 pediatric patients treated on Dana-Farber Cancer Institute (DFCI) protocols with ALL at first or second relapse were tested for TEL/AML1 using reverse transcriptase-polymerase chain reaction (RT-PCR).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP219216.RA7IrBPkSkRE1Lkw2Baysoat_RS-BpTeLWAPEWe4ACkrI130_provenance.
- NP219216.RA7IrBPkSkRE1Lkw2Baysoat_RS-BpTeLWAPEWe4ACkrI130_assertion evidence source_evidence_literature NP219216.RA7IrBPkSkRE1Lkw2Baysoat_RS-BpTeLWAPEWe4ACkrI130_provenance.
- NP219216.RA7IrBPkSkRE1Lkw2Baysoat_RS-BpTeLWAPEWe4ACkrI130_assertion SIO_000772 9845546 NP219216.RA7IrBPkSkRE1Lkw2Baysoat_RS-BpTeLWAPEWe4ACkrI130_provenance.
- NP219216.RA7IrBPkSkRE1Lkw2Baysoat_RS-BpTeLWAPEWe4ACkrI130_assertion wasDerivedFrom befree-20140225 NP219216.RA7IrBPkSkRE1Lkw2Baysoat_RS-BpTeLWAPEWe4ACkrI130_provenance.
- NP219216.RA7IrBPkSkRE1Lkw2Baysoat_RS-BpTeLWAPEWe4ACkrI130_assertion wasGeneratedBy ECO_0000203 NP219216.RA7IrBPkSkRE1Lkw2Baysoat_RS-BpTeLWAPEWe4ACkrI130_provenance.